Brief: Invivyd Announces Positive Initial Results from Ongoing CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of COVID-19

Invivyd

18/12/2023 12:21

Dec 18 (Reuters) - Invivyd Inc  IVVD.O :
    * INVIVYD ANNOUNCES POSITIVE INITIAL RESULTS FROM ONGOING
CANOPY
PHASE 3 PIVOTAL CLINICAL TRIAL INVESTIGATING VYD222 FOR THE
PREVENTION OF COVID-19
    * INVIVYD INC: VYD222 PRODUCED HIGH SERUM VIRUS NEUTRALIZING
ANTIBODY TITER LEVELS IN IMMUNOCOMPROMISED PARTICIPANTS
    * INVIVYD INC: DATA SUPPORTIVE OF AN IMMUNOBRIDGING APPROACH
TO
EVADE STUDY OF ADINTREVIMAB
    * INVIVYD INC: OVERALL FAVORABLE SAFETY AND TOLERABILITY
PROFILE
OF VYD222 INCLUDING NO STUDY DRUG-RELATED SERIOUS ADVERSE EVENTS
(SAES) TO DATE
    * INVIVYD INC: VYD222 DEMONSTRATES CONTINUED IN-VITRO
NEUTRALIZATION ACTIVITY AGAINST MAJOR SARS-COV-2 VARIANTS,
INCLUDING AGAINST HV.1

Source text for Eikon:  ID:nGNX90wxvR 
Further company coverage:  IVVD.O 

 ((Reuters.Briefs@thomsonreuters.com;))